-
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.
JCI InsightUenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H, Hunt M, Drow T, Tewari R, Cook PJ, Yang SJ, Cerosaletti K, Schweinoch D, Guiastrennec B, James E, Patel C, Chen TF, Buckner JH, Rawlings DJ, Wickham TJ, Mueller KT -
Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis.
Nature CommunicationsJames EA, Holers VM, Iyer R, Prideaux EB, Rao NL, Rims C, Muir VS, Posso SE, Bloom MS, Zia A, Elliott SE, Adamska JZ, Ai R, Brewer RC, Seifert JA, Moss L, Barzideh S, Demoruelle MK, Striebich CC, Okamoto Y, Sainbayar E, Crook AA, Peterson RA, Vanderlinden LA, Wang W, Boyle DL, Robinson WH, Buckner JH, Firestein GS, Deane KD -
Trimodal single-cell profiling reveals a novel pediatric CD8αα(+) T cell subset and broad age-related molecular reprogramming across the T cell compartment.
Nat ImmunolThomson Z, He Z, Swanson E, Henderson K, Phalen C, Zaim SR, Pebworth MP, Okada LY, Heubeck AT, Roll CR, Hernandez V, Weiss M, Genge PC, Reading J, Giles JR, Manne S, Dougherty J, Jasen CJ, Greenplate AR, Becker LA, Graybuck LT, Vasaikar SV, Szeto GL, Savage AK, Speake C, Buckner JH, Li XJ, Bumol TF, Wherry EJ, Torgerson TR, Vella LA, Henrickson SE, Skene PJ, Gustafson CE -
Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes.
Communications BiologyNewman JRB, Long SA, Speake C, Greenbaum CJ, Cerosaletti K, Rich SS, Onengut-Gumuscu S, McIntyre LM, Buckner JH, Concannon P -
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Diabetes CareLibman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC, Type 1 Diabetes TrialNet Study Group -
Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
Immunol RevSingh N, Hocking AM, Buckner JH -
Dysregulated IFN-γ signals promote autoimmunity in STAT1 gain-of-function syndrome.
Sci Transl MedLargent AD, Lambert K, Chiang K, Shumlak N, Liggitt D, Oukka M, Torgerson TR, Buckner JH, Allenspach EJ, Rawlings DJ, Jackson SW -
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies.
JCI InsightKlebanoff SD, Rodda LB, Morishima C, Wener MH, Yuzefpolskiy Y, Bettelli E, Buckner JH, Speake C, Pepper M, Campbell DJ -
Down syndrome: insights into autoimmune mechanisms.
Nat Rev RheumatolKhor B, Buckner JH -
Translational Immunology: Applying fundamental discoveries to human health and autoimmune diseases.
European Journal of ImmunologyBuckner JH -
PTPN22 R620W gene editing in T cells enhances low avidity TCR responses.
ElifeAnderson W, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Buckner JH, Rawlings DJ -
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Nat CommunJaycox JR, Lucas C, Yildirim I, Dai Y, Wang EY, Monteiro V, Lord S, Carlin J, Kita M, Buckner JH, Ma S, Campbell M, Ko A, Omer S, Lucas CL, Speake C, Iwasaki A, Ring AM -
Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis.
The Journal of Experimental MedicineSo L, Obata-Ninomiya K, Hu A, Muir VS, Takamori A, Song J, Buckner JH, Savan R, Ziegler SF -
Cytotoxic CD8(+) T cells target citrullinated antigens in rheumatoid arthritis.
Nature CommunicationsMoon JS, Younis S, Ramadoss NS, Iyer R, Sheth K, Sharpe O, Rao NL, Becart S, Carman JA, James EA, Buckner JH, Deane KD, Holers VM, Goodman SM, Donlin LT, Davis MM, Robinson WH -
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.
Journal of the Endocrine SocietyKinney M, You L, Sims EK, Wherrett D, Schatz D, Lord S, Krischer J, Russell WE, Gottlieb PA, Libman I, Buckner JH, DiMeglio LA, Herold K, Steck A
